U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C28H54N8
Molecular Weight 502.783
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PLERIXAFOR

SMILES

C1CNCCNCCCN(CCNC1)Cc2ccc(cc2)CN3CCCNCCNCCCNCC3

InChI

InChIKey=YIQPUIGJQJDJOS-UHFFFAOYSA-N
InChI=1S/C28H54N8/c1-9-29-15-17-31-13-3-21-35(23-19-33-11-1)25-27-5-7-28(8-6-27)26-36-22-4-14-32-18-16-30-10-2-12-34-20-24-36/h5-8,29-34H,1-4,9-26H2

HIDE SMILES / InChI
Plerixafor is a bicyclam molecule, which has been identified as a specific antagonist of CXCR4. It had originally been developed as an inhibitor of T-tropic human immunodeficiency virus, but later demonstrated to be an effective mobilizer of hematopoietic stem cells. Plerixafor was approved by FDA for autologous transplantation (in combination with granulocyte-colony stimulating factor) in patients with non-Hodgkin's lymphoma and multiple myeloma under the name Mozobil.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P61073
Gene ID: 7852.0
Gene Symbol: CXCR4
Target Organism: Homo sapiens (Human)
44.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
MOZOBIL

Approved Use

Mozobil (plerixafor) injection is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM).

Launch Date

1.22929925E12
Primary
MOZOBIL

Approved Use

Mozobil (plerixafor) injection is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM).

Launch Date

1.22929925E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1029 ng/mL
240 μg/kg bw single, subcutaneous
dose: 240 μg/kg bw
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
PLERIXAFOR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
5260 ng × h/mL
240 μg/kg bw single, subcutaneous
dose: 240 μg/kg bw
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
PLERIXAFOR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5.6 h
240 μg/kg bw single, subcutaneous
dose: 240 μg/kg bw
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
PLERIXAFOR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
160 ug/kg/h multiple, intravenous
Highest studied dose
Dose: 160 ug/kg/h
Route: intravenous
Route: multiple
Dose: 160 ug/kg/h
Sources:
unhealthy, 40.2 years
n = 3
Health Status: unhealthy
Condition: HIV-1 Infection
Age Group: 40.2 years
Sex: M+F
Population Size: 3
Sources:
Disc. AE: Premature ventricular contractions...
AEs leading to
discontinuation/dose reduction:
Premature ventricular contractions (1 patient)
Sources:
20 ug/kg/h multiple, intravenous
Dose: 20 ug/kg/h
Route: intravenous
Route: multiple
Dose: 20 ug/kg/h
Sources:
unhealthy, 40.2 years
n = 8
Health Status: unhealthy
Condition: HIV-1 Infection
Age Group: 40.2 years
Sex: M+F
Population Size: 8
Sources:
Disc. AE: Hepatic enzyme increased, Orthostatic hypotension...
AEs leading to
discontinuation/dose reduction:
Hepatic enzyme increased (1 patient)
Orthostatic hypotension (1 patient)
Sources:
40 ug/kg/h multiple, intravenous
Dose: 40 ug/kg/h
Route: intravenous
Route: multiple
Dose: 40 ug/kg/h
Sources:
unhealthy, 40.2 years
n = 8
Health Status: unhealthy
Condition: HIV-1 Infection
Age Group: 40.2 years
Sex: M+F
Population Size: 8
Sources:
Disc. AE: Ventricular ectopics...
AEs leading to
discontinuation/dose reduction:
Ventricular ectopics (1 patient)
Sources:
5 ug/kg/h multiple, intravenous
Dose: 5 ug/kg/h
Route: intravenous
Route: multiple
Dose: 5 ug/kg/h
Sources:
unhealthy, 40.2 years
n = 7
Health Status: unhealthy
Condition: HIV-1 Infection
Age Group: 40.2 years
Sex: M+F
Population Size: 7
Sources:
Disc. AE: Thrombocytopenia...
AEs leading to
discontinuation/dose reduction:
Thrombocytopenia (serious, 1 patient)
Sources:
80 ug/kg/h multiple, intravenous
Dose: 80 ug/kg/h
Route: intravenous
Route: multiple
Dose: 80 ug/kg/h
Sources:
unhealthy, 40.2 years
n = 5
Health Status: unhealthy
Condition: HIV-1 Infection
Age Group: 40.2 years
Sex: M+F
Population Size: 5
Sources:
Disc. AE: Paresthesia...
AEs leading to
discontinuation/dose reduction:
Paresthesia (1 patient)
Sources:
160 ug/kg single, oral
Dose: 160 ug/kg
Route: oral
Route: single
Dose: 160 ug/kg
Sources:
healthy, >18 years
n = 3
Health Status: healthy
Age Group: >18 years
Sex: M+F
Population Size: 3
Sources:
80 ug/kg single, intravenous
Dose: 80 ug/kg
Route: intravenous
Route: single
Dose: 80 ug/kg
Sources:
healthy, >18 years
n = 12
Health Status: healthy
Age Group: >18 years
Sex: M+F
Population Size: 12
Sources:
Other AEs: Diaphoresis...
Other AEs:
Diaphoresis (1 patient)
Sources:
320 ug/kg single, subcutaneous
Highest studied dose
Dose: 320 ug/kg
Route: subcutaneous
Route: single
Dose: 320 ug/kg
Sources: Page: p. 83
healthy, adult
n = 10
Health Status: healthy
Age Group: adult
Population Size: 10
Sources: Page: p. 83
Other AEs: Injection site erythema, Paresthesia...
Other AEs:
Injection site erythema
Paresthesia
Chest discomfort
Sources: Page: p. 83
0.24 mg/kg 1 times / day multiple, subcutaneous
Recommended
Dose: 0.24 mg/kg, 1 times / day
Route: subcutaneous
Route: multiple
Dose: 0.24 mg/kg, 1 times / day
Sources: Page: p.97
unhealthy, adult
n = 72
Health Status: unhealthy
Age Group: adult
Population Size: 72
Sources: Page: p.97
Disc. AE: Anxiety, Arrhythmia...
AEs leading to
discontinuation/dose reduction:
Anxiety (1 patient)
Arrhythmia (1 patient)
Erythema (1 patient)
Decreased appetite (1 patient)
Eructation (1 patient)
Liver function test abnormal (1 patient)
Nausea (2 patients)
Vomiting (2 patients)
Postural hypotension (1 patient)
Sinus tachycardia (1 patient)
Staphylococcal bacteremia (1 patient)
Insomnia (1 patient)
Sources: Page: p.97
AEs

AEs

AESignificanceDosePopulation
Premature ventricular contractions 1 patient
Disc. AE
160 ug/kg/h multiple, intravenous
Highest studied dose
Dose: 160 ug/kg/h
Route: intravenous
Route: multiple
Dose: 160 ug/kg/h
Sources:
unhealthy, 40.2 years
n = 3
Health Status: unhealthy
Condition: HIV-1 Infection
Age Group: 40.2 years
Sex: M+F
Population Size: 3
Sources:
Hepatic enzyme increased 1 patient
Disc. AE
20 ug/kg/h multiple, intravenous
Dose: 20 ug/kg/h
Route: intravenous
Route: multiple
Dose: 20 ug/kg/h
Sources:
unhealthy, 40.2 years
n = 8
Health Status: unhealthy
Condition: HIV-1 Infection
Age Group: 40.2 years
Sex: M+F
Population Size: 8
Sources:
Orthostatic hypotension 1 patient
Disc. AE
20 ug/kg/h multiple, intravenous
Dose: 20 ug/kg/h
Route: intravenous
Route: multiple
Dose: 20 ug/kg/h
Sources:
unhealthy, 40.2 years
n = 8
Health Status: unhealthy
Condition: HIV-1 Infection
Age Group: 40.2 years
Sex: M+F
Population Size: 8
Sources:
Ventricular ectopics 1 patient
Disc. AE
40 ug/kg/h multiple, intravenous
Dose: 40 ug/kg/h
Route: intravenous
Route: multiple
Dose: 40 ug/kg/h
Sources:
unhealthy, 40.2 years
n = 8
Health Status: unhealthy
Condition: HIV-1 Infection
Age Group: 40.2 years
Sex: M+F
Population Size: 8
Sources:
Thrombocytopenia serious, 1 patient
Disc. AE
5 ug/kg/h multiple, intravenous
Dose: 5 ug/kg/h
Route: intravenous
Route: multiple
Dose: 5 ug/kg/h
Sources:
unhealthy, 40.2 years
n = 7
Health Status: unhealthy
Condition: HIV-1 Infection
Age Group: 40.2 years
Sex: M+F
Population Size: 7
Sources:
Paresthesia 1 patient
Disc. AE
80 ug/kg/h multiple, intravenous
Dose: 80 ug/kg/h
Route: intravenous
Route: multiple
Dose: 80 ug/kg/h
Sources:
unhealthy, 40.2 years
n = 5
Health Status: unhealthy
Condition: HIV-1 Infection
Age Group: 40.2 years
Sex: M+F
Population Size: 5
Sources:
Diaphoresis 1 patient
80 ug/kg single, intravenous
Dose: 80 ug/kg
Route: intravenous
Route: single
Dose: 80 ug/kg
Sources:
healthy, >18 years
n = 12
Health Status: healthy
Age Group: >18 years
Sex: M+F
Population Size: 12
Sources:
Chest discomfort
320 ug/kg single, subcutaneous
Highest studied dose
Dose: 320 ug/kg
Route: subcutaneous
Route: single
Dose: 320 ug/kg
Sources: Page: p. 83
healthy, adult
n = 10
Health Status: healthy
Age Group: adult
Population Size: 10
Sources: Page: p. 83
Injection site erythema
320 ug/kg single, subcutaneous
Highest studied dose
Dose: 320 ug/kg
Route: subcutaneous
Route: single
Dose: 320 ug/kg
Sources: Page: p. 83
healthy, adult
n = 10
Health Status: healthy
Age Group: adult
Population Size: 10
Sources: Page: p. 83
Paresthesia
320 ug/kg single, subcutaneous
Highest studied dose
Dose: 320 ug/kg
Route: subcutaneous
Route: single
Dose: 320 ug/kg
Sources: Page: p. 83
healthy, adult
n = 10
Health Status: healthy
Age Group: adult
Population Size: 10
Sources: Page: p. 83
Anxiety 1 patient
Disc. AE
0.24 mg/kg 1 times / day multiple, subcutaneous
Recommended
Dose: 0.24 mg/kg, 1 times / day
Route: subcutaneous
Route: multiple
Dose: 0.24 mg/kg, 1 times / day
Sources: Page: p.97
unhealthy, adult
n = 72
Health Status: unhealthy
Age Group: adult
Population Size: 72
Sources: Page: p.97
Arrhythmia 1 patient
Disc. AE
0.24 mg/kg 1 times / day multiple, subcutaneous
Recommended
Dose: 0.24 mg/kg, 1 times / day
Route: subcutaneous
Route: multiple
Dose: 0.24 mg/kg, 1 times / day
Sources: Page: p.97
unhealthy, adult
n = 72
Health Status: unhealthy
Age Group: adult
Population Size: 72
Sources: Page: p.97
Decreased appetite 1 patient
Disc. AE
0.24 mg/kg 1 times / day multiple, subcutaneous
Recommended
Dose: 0.24 mg/kg, 1 times / day
Route: subcutaneous
Route: multiple
Dose: 0.24 mg/kg, 1 times / day
Sources: Page: p.97
unhealthy, adult
n = 72
Health Status: unhealthy
Age Group: adult
Population Size: 72
Sources: Page: p.97
Eructation 1 patient
Disc. AE
0.24 mg/kg 1 times / day multiple, subcutaneous
Recommended
Dose: 0.24 mg/kg, 1 times / day
Route: subcutaneous
Route: multiple
Dose: 0.24 mg/kg, 1 times / day
Sources: Page: p.97
unhealthy, adult
n = 72
Health Status: unhealthy
Age Group: adult
Population Size: 72
Sources: Page: p.97
Erythema 1 patient
Disc. AE
0.24 mg/kg 1 times / day multiple, subcutaneous
Recommended
Dose: 0.24 mg/kg, 1 times / day
Route: subcutaneous
Route: multiple
Dose: 0.24 mg/kg, 1 times / day
Sources: Page: p.97
unhealthy, adult
n = 72
Health Status: unhealthy
Age Group: adult
Population Size: 72
Sources: Page: p.97
Insomnia 1 patient
Disc. AE
0.24 mg/kg 1 times / day multiple, subcutaneous
Recommended
Dose: 0.24 mg/kg, 1 times / day
Route: subcutaneous
Route: multiple
Dose: 0.24 mg/kg, 1 times / day
Sources: Page: p.97
unhealthy, adult
n = 72
Health Status: unhealthy
Age Group: adult
Population Size: 72
Sources: Page: p.97
Liver function test abnormal 1 patient
Disc. AE
0.24 mg/kg 1 times / day multiple, subcutaneous
Recommended
Dose: 0.24 mg/kg, 1 times / day
Route: subcutaneous
Route: multiple
Dose: 0.24 mg/kg, 1 times / day
Sources: Page: p.97
unhealthy, adult
n = 72
Health Status: unhealthy
Age Group: adult
Population Size: 72
Sources: Page: p.97
Postural hypotension 1 patient
Disc. AE
0.24 mg/kg 1 times / day multiple, subcutaneous
Recommended
Dose: 0.24 mg/kg, 1 times / day
Route: subcutaneous
Route: multiple
Dose: 0.24 mg/kg, 1 times / day
Sources: Page: p.97
unhealthy, adult
n = 72
Health Status: unhealthy
Age Group: adult
Population Size: 72
Sources: Page: p.97
Sinus tachycardia 1 patient
Disc. AE
0.24 mg/kg 1 times / day multiple, subcutaneous
Recommended
Dose: 0.24 mg/kg, 1 times / day
Route: subcutaneous
Route: multiple
Dose: 0.24 mg/kg, 1 times / day
Sources: Page: p.97
unhealthy, adult
n = 72
Health Status: unhealthy
Age Group: adult
Population Size: 72
Sources: Page: p.97
Staphylococcal bacteremia 1 patient
Disc. AE
0.24 mg/kg 1 times / day multiple, subcutaneous
Recommended
Dose: 0.24 mg/kg, 1 times / day
Route: subcutaneous
Route: multiple
Dose: 0.24 mg/kg, 1 times / day
Sources: Page: p.97
unhealthy, adult
n = 72
Health Status: unhealthy
Age Group: adult
Population Size: 72
Sources: Page: p.97
Nausea 2 patients
Disc. AE
0.24 mg/kg 1 times / day multiple, subcutaneous
Recommended
Dose: 0.24 mg/kg, 1 times / day
Route: subcutaneous
Route: multiple
Dose: 0.24 mg/kg, 1 times / day
Sources: Page: p.97
unhealthy, adult
n = 72
Health Status: unhealthy
Age Group: adult
Population Size: 72
Sources: Page: p.97
Vomiting 2 patients
Disc. AE
0.24 mg/kg 1 times / day multiple, subcutaneous
Recommended
Dose: 0.24 mg/kg, 1 times / day
Route: subcutaneous
Route: multiple
Dose: 0.24 mg/kg, 1 times / day
Sources: Page: p.97
unhealthy, adult
n = 72
Health Status: unhealthy
Age Group: adult
Population Size: 72
Sources: Page: p.97
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
inconclusive
inconclusive
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no
no
no
no
no
no
no
no
no
Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Curcumin modulates SDF-1alpha/CXCR4-induced migration of human retinal endothelial cells (HRECs).
2008 Aug
Microenvironmental considerations in the application of human mesenchymal stem cells in regenerative therapies.
2008 Dec
A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma.
2008 Nov
A novel CXCR4 antagonist for hematopoietic stem cell mobilization.
2008 Nov
Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells.
2008 Nov
Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.
2008 Sep
Targeted antagonism of CXCR4 mobilizes progenitor cells under investigation for cardiovascular disease.
2009
A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study.
2009
CXCR4 and mobilization of hematopoietic precursors.
2009
Plerixafor: in patients with non-Hodgkin's lymphoma or multiple myeloma.
2009
CXCR4 chemokine receptor antagonists: perspectives in SCLC.
2009 Apr
Bis-14-membered ring diketal diamines: synthesis and evaluation of their anti-HIV and anti-tumoral activities.
2009 Aug
Tumor biology and cancer therapy - an evolving relationship.
2009 Aug 13
BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells.
2009 Aug 13
Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol.
2009 Dec
Plerixafor.
2009 Feb
Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.
2009 Feb
Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.
2009 Jan
CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers.
2009 Jan
Plerixafor approved for autologous hematopoietic stem-cell transplantation.
2009 Jan 15
Plerixafor hydrochloride: a novel agent for the mobilization of peripheral blood stem cells.
2009 Jul
Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience.
2009 Jun
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.
2009 Jun 4
AMD3100 is a CXCR7 ligand with allosteric agonist properties.
2009 May
Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting.
2009 May 7
[Stem cell harvesting after plerixafor treatment].
2009 Nov 16
[Mobilisation of haematopoietic stem cells with plerixafor--secondary publication].
2009 Nov 2
Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib.
2009 Oct
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).
2009 Oct
Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.
2009 Oct 1
Advances in mobilization for the optimization of autologous stem cell transplantation.
2009 Sep
Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global gene and microRNA expression signatures.
2009 Sep 17
CXCR4 in clinical hematology.
2010
Anticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes.
2010
Molecular Medicine - CHI's 17th International Tri-Conference: Mastering Medicinal Chemistry - CHI's Seventh Annual Conference.
2010 Apr
Binding of multivalent anionic porphyrins to V3 loop fragments of an HIV-1 envelope and their antiviral activity.
2010 Apr 1
Plerixafor (Mozobil).
2010 Apr 5
Plerixafor and pegylated filgrastim: a case of safe and effective hematopoietic stem cell mobilization.
2010 Aug
Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients.
2010 Feb
Synthesis and structure-activity relationships of azamacrocyclic C-X-C chemokine receptor 4 antagonists: analogues containing a single azamacrocyclic ring are potent inhibitors of T-cell tropic (X4) HIV-1 replication.
2010 Feb 11
Plerixafor for stem cell mobilization in patients with non-Hodgkin's lymphoma and multiple myeloma.
2010 Jan
Peripheral blood stem cell mobilization tactics.
2010 Jan
A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairment.
2010 Jan
Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization.
2010 Jan
Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization.
2010 Jan
A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41.
2010 Jul
Plerixafor given before the third leukapheresis to rescue an unsuccessful stem cell mobilization with CY and G-CSF.
2010 Jun
Expression and function of CXCL12/CXCR4 in rat urinary bladder with cyclophosphamide-induced cystitis.
2010 Mar
Plerixafor: a peripheral blood stem cell mobilizer.
2010 May
Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation.
2010 May
Patents

Sample Use Guides

Begin treatment with plerixafor (Mozobil) after the patient has received G-CSF once daily for four days. The recommended dose of plerixafor by subcutaneous injection is based on body weight: 20 mg fixed dose or 0.24 mg/kg of body weight for patients weighing ≤83 kg; 0.24 mg/kg of body weight for patients weighing >83 kg. Administer by subcutaneous injection approximately 11 hours prior to initiation of apheresis.
Route of Administration: Other
Human colorectal cancer cell line SW480 was treated with plerixafor at different final concentrations (10, 100, 1000 ng/ml) for 2h. Then, CXCL12 was added daily at 20 ng/mL. MTT assays were performed after 24, 48 and 72 h of plerixafor treatment. Cell viability was significantly suppressed by the drug in a dose-dependent manner. The drug (100 and 1000 ng/mL) significantly inhibited the invasion ability of SW480 cells.
Name Type Language
PLERIXAFOR
DASH   EMA EPAR   INN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
PLERIXAFOR [WHO-DD]
Common Name English
PLERIXAFOR [ORANGE BOOK]
Common Name English
PLERIXAFOR [JAN]
Common Name English
PLERIXAFOR [EMA EPAR]
Common Name English
PLERIXAFOR [USAN]
Common Name English
PLERIXAFOR [MART.]
Common Name English
PLERIXAFOR [INN]
Common Name English
PLERIXAFOR [VANDF]
Common Name English
PLERIXAFOR [MI]
Common Name English
1,1'-(1,4-PHENYLENEBIS(METHYLENE))BIS-1,4,8,11-TETRAAZACYCLOTETRADECANE
Systematic Name English
1,4,8,11-TETRAAZACYCLOTETRADECANE, 1,1'-(1,4-PHENYLENEBIS(METHYLENE))BIS-
Systematic Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 167903
Created by admin on Fri Jun 25 23:29:25 UTC 2021 , Edited by admin on Fri Jun 25 23:29:25 UTC 2021
FDA ORPHAN DRUG 346111
Created by admin on Fri Jun 25 23:29:25 UTC 2021 , Edited by admin on Fri Jun 25 23:29:25 UTC 2021
WHO-VATC QL03AX16
Created by admin on Fri Jun 25 23:29:25 UTC 2021 , Edited by admin on Fri Jun 25 23:29:25 UTC 2021
EMA ASSESSMENT REPORTS MOZOBIL (AUTHORIZED: HEMATOPOIETIC STEM CELL TRANSPLANTATION)
Created by admin on Fri Jun 25 23:29:25 UTC 2021 , Edited by admin on Fri Jun 25 23:29:25 UTC 2021
NDF-RT N0000178324
Created by admin on Fri Jun 25 23:29:25 UTC 2021 , Edited by admin on Fri Jun 25 23:29:25 UTC 2021
WHO-ATC L03AX16
Created by admin on Fri Jun 25 23:29:25 UTC 2021 , Edited by admin on Fri Jun 25 23:29:25 UTC 2021
EMA ASSESSMENT REPORTS MOZOBIL (AUTHORIZED: LYMPHOMA)
Created by admin on Fri Jun 25 23:29:25 UTC 2021 , Edited by admin on Fri Jun 25 23:29:25 UTC 2021
EMA ASSESSMENT REPORTS MOZOBIL (AUTHORIZED: MULTIPLE MYELOMA)
Created by admin on Fri Jun 25 23:29:25 UTC 2021 , Edited by admin on Fri Jun 25 23:29:25 UTC 2021
EU-Orphan Drug EU/3/11/931
Created by admin on Fri Jun 25 23:29:25 UTC 2021 , Edited by admin on Fri Jun 25 23:29:25 UTC 2021
NDF-RT N0000178326
Created by admin on Fri Jun 25 23:29:25 UTC 2021 , Edited by admin on Fri Jun 25 23:29:25 UTC 2021
NCI_THESAURUS C63817
Created by admin on Fri Jun 25 23:29:25 UTC 2021 , Edited by admin on Fri Jun 25 23:29:25 UTC 2021
Code System Code Type Description
EVMPD
SUB28849
Created by admin on Fri Jun 25 23:29:25 UTC 2021 , Edited by admin on Fri Jun 25 23:29:25 UTC 2021
PRIMARY
IUPHAR
844
Created by admin on Fri Jun 25 23:29:25 UTC 2021 , Edited by admin on Fri Jun 25 23:29:25 UTC 2021
PRIMARY
PUBCHEM
65015
Created by admin on Fri Jun 25 23:29:25 UTC 2021 , Edited by admin on Fri Jun 25 23:29:25 UTC 2021
PRIMARY
RXCUI
733003
Created by admin on Fri Jun 25 23:29:25 UTC 2021 , Edited by admin on Fri Jun 25 23:29:25 UTC 2021
PRIMARY RxNorm
DRUG CENTRAL
4410
Created by admin on Fri Jun 25 23:29:25 UTC 2021 , Edited by admin on Fri Jun 25 23:29:25 UTC 2021
PRIMARY
ChEMBL
CHEMBL18442
Created by admin on Fri Jun 25 23:29:25 UTC 2021 , Edited by admin on Fri Jun 25 23:29:25 UTC 2021
PRIMARY
CAS
110078-46-1
Created by admin on Fri Jun 25 23:29:25 UTC 2021 , Edited by admin on Fri Jun 25 23:29:25 UTC 2021
PRIMARY
DRUG BANK
DB06809
Created by admin on Fri Jun 25 23:29:25 UTC 2021 , Edited by admin on Fri Jun 25 23:29:25 UTC 2021
PRIMARY
NCI_THESAURUS
C1777
Created by admin on Fri Jun 25 23:29:25 UTC 2021 , Edited by admin on Fri Jun 25 23:29:25 UTC 2021
PRIMARY
INN
8513
Created by admin on Fri Jun 25 23:29:25 UTC 2021 , Edited by admin on Fri Jun 25 23:29:25 UTC 2021
PRIMARY
FDA UNII
S915P5499N
Created by admin on Fri Jun 25 23:29:25 UTC 2021 , Edited by admin on Fri Jun 25 23:29:25 UTC 2021
PRIMARY
WIKIPEDIA
PLERIXAFOR
Created by admin on Fri Jun 25 23:29:25 UTC 2021 , Edited by admin on Fri Jun 25 23:29:25 UTC 2021
PRIMARY
MERCK INDEX
M8919
Created by admin on Fri Jun 25 23:29:25 UTC 2021 , Edited by admin on Fri Jun 25 23:29:25 UTC 2021
PRIMARY Merck Index